The health of Valeant Pharmaceuticals International Inc’s Michael Pearson is improving, the company said on Thursday, but CNBC reported that there was debate within the board over whether he was ready to return to work.
Pearson, who joined Valeant as chief executive in 2010, was hospitalized with severe pneumonia in late December.
The company named former Chief Financial Officer Howard Schiller as interim CEO in January.
CNBC, citing a source, said Pearson was ready to return but the board was debating whether he should. (bit.ly/20X0uU8)
(Reporting by Natalie Grover in Bengaluru; Editing by Ted Kerr)
Source: Reuters
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.
